FDA NDA submission summary data draft guidance expected out before year-end.
This article was originally published in The Tan Sheet
FDA DRAFT GUIDANCE ON SUMMARY DATA IN NDA SUBMISSIONS, including Rx-to-OTC switches, is expected to be published by the agency before the end of the year. Under the provisions of Sen. James Jeffords' (R-Vt.) proposed Senate FDA reform bill (S 830), FDA has 12 months following passage of the legislation to provide industry with a guidance "that describes when abbreviated study reports may be submitted, in lieu of full reports," with an NDA, such as for a switch application, according to bill language as reported out of Jeffords' Senate Labor & Human Resources Committee.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC